Teva Pharms Faces Major EU Antitrust Fine for Undercutting Competitors

Israeli pharmaceutical company Teva Pharmaceuticals is facing a significant backlash from the European Union's antitrust regulator. The company is accused of deliberately undermining its rivals' achievements in the generics market, a severe violation of antitrust legislation. This case relates to several communities involved in the approval processes for generics, where Teva allegedly leveraged its market position to weaken its competitors' viability.

Continue reading